Alpha-galactosidase, A enzyme replacement therapy, has been shown to decrease the severity of neuropathic pain, improve glomerular filtration rate, reverse the pathology in glomerular architecture, and reduce the QRS-complex duration when administered intravenously at a dose of 0.2 mg/kg every 15 days for six months in patients with Fabry disease [49]. Here, GLA is linked to Fabry disease.